

Immune-related toxicities of checkpoint inhibitors: me

Nature Reviews Drug Discovery

21, 495-508

DOI: [10.1038/s41573-021-00259-5](https://doi.org/10.1038/s41573-021-00259-5)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Modulation of Covid-19 cytokine storm by tocilizumab. <i>Journal of Medical Virology</i> , 2022, 94, 823-828.	2.5	9
2	Pathogenic mitochondrial dysfunction and metabolic abnormalities. <i>Biochemical Pharmacology</i> , 2021, 193, 114809.	2.0	21
3	Targeted Mass Spectrometry Enables Multiplexed Quantification of Immunomodulatory Proteins in Clinical Biospecimens. <i>Frontiers in Immunology</i> , 2021, 12, 765898.	2.2	13
4	Human immune diversity: from evolution to modernity. <i>Nature Immunology</i> , 2021, 22, 1479-1489.	7.0	64
5	Adverse Events of Immune Checkpoint Inhibitors Therapy for Urologic Cancer Patients in Clinical Trials: A Collaborative Systematic Review and Meta-analysis. <i>European Urology</i> , 2022, 81, 414-425.	0.9	40
6	Semiconducting Polymer Nano-regulators with Cascading Activation for Photodynamic Cancer Immunotherapy. <i>Angewandte Chemie</i> , 2022, 134, .	1.6	9
7	Semiconducting Polymer Nano-regulators with Cascading Activation for Photodynamic Cancer Immunotherapy. <i>Angewandte Chemie - International Edition</i> , 2022, 61, .	7.2	58
9	Overview of Immune Checkpoint Inhibitors in Gynecological Cancer Treatment. <i>Cancers</i> , 2022, 14, 631.	1.7	19
11	Novel antibodies which have an impact on immune status after allogeneic hematopoietic cell transplantation. <i>Expert Review of Hematology</i> , 2022, , 1-7.	1.0	0
12	Immune Checkpoint Inhibitors as a Threat to the Hypothalamus-Pituitary Axis: A Completed Puzzle. <i>Cancers</i> , 2022, 14, 1057.	1.7	4
13	Immunotherapy Associated Neurotoxicity in Pediatric Oncology. <i>Frontiers in Oncology</i> , 2022, 12, 836452.	1.3	5
14	Targeting oncogene and non-oncogene addiction to inflame the tumour microenvironment. <i>Nature Reviews Drug Discovery</i> , 2022, 21, 440-462.	21.5	58
15	Poliosis Is Associated with Response to Checkpoint-Inhibitor Therapy: A Case Report of Two Patients with Multifocal Metastatic Melanoma. <i>Immuno</i> , 2022, 2, 307-316.	0.6	2
16	Case Report: Delayed Onset Multi-Organ Toxicities in a Melanoma Patient Achieving Complete Response to BRAF/MEK Inhibition. <i>Frontiers in Oncology</i> , 2022, 12, 836845.	1.3	2
17	Letter comments on anti-PD(L)1 immunotherapies in patients with cancer and with pre-existing systemic sclerosis: a post-marketed safety assessment study. <i>European Journal of Cancer</i> , 2022, 165, 205-207.	1.3	0
18	Immunotherapy in non-small cell lung cancer: rationale, recent advances and future perspectives. <i>Precision Clinical Medicine</i> , 2021, 4, 258-270.	1.3	18
19	Grading Central Diabetes Insipidus Induced by Immune Checkpoint Inhibitors: A Challenging Task. <i>Frontiers in Endocrinology</i> , 2022, 13, 840971.	1.5	2
20	Sodium Tanshinone IIA Sulfonate as a Potent IDO1/TDO2 Dual Inhibitor Enhances Anti-PD1 Therapy for Colorectal Cancer in Mice. <i>Frontiers in Pharmacology</i> , 2022, 13, 870848.	1.6	9

#	ARTICLE	IF	CITATIONS
21	Immune checkpoint inhibitor-related hypophysitis. <i>Best Practice and Research in Clinical Endocrinology and Metabolism</i> , 2022, 36, 101668.	2.2	11
22	T Lymphocyte Exhaustion During Human and Experimental Visceral Leishmaniasis. <i>Frontiers in Immunology</i> , 2022, 13, 835711.	2.2	14
23	Recent Advances in Engineering Nanomedicines for Second Near-Infrared Photothermal-Combinational Immunotherapy. <i>Nanomaterials</i> , 2022, 12, 1656.	1.9	9
24	Prognostic significance of the immune checkpoint HLA-G/ILT-4 in the survival of patients with gastric cancer. <i>International Immunopharmacology</i> , 2022, 109, 108798.	1.7	4
25	Challenges and the Evolving Landscape of Assessing Blood-Based PD-L1 Expression as a Biomarker for Anti-PD-(L)1 Immunotherapy. <i>Biomedicines</i> , 2022, 10, 1181.	1.4	8
26	Oncologic emergencies and urgencies: A comprehensive review. <i>Ca-A Cancer Journal for Clinicians</i> , 2022, 72, 570-593.	157.7	18
27	Serum immune modulators associated with immune-related toxicities and efficacy of atezolizumab in patients with non-small cell lung cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 2963-2974.	1.2	3
28	Peripheral Blood Lymphocyte Subsets Predict the Efficacy of Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	8
29	Cancer as microenvironmental, systemic and environmental diseases: opportunity for transdisciplinary microbiomics science. <i>Gut</i> , 2022, 71, 2107-2122.	6.1	28
30	Injectable pH-responsive hydrogel for combinatorial chemoimmunotherapy tailored to the tumor microenvironment. <i>Journal of Nanobiotechnology</i> , 2022, 20, .	4.2	14
31	Case report: A case of acute mastitis associated with reactive cutaneous capillary endothelial proliferation after camrelizumab treatment: A new immune-related adverse event. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	2
32	Eosinophil as a biomarker for diagnosis, prediction, and prognosis evaluation of severe checkpoint inhibitor pneumonitis. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	3
33	Efficacy and Safety of Immune Checkpoint Inhibitors for Advanced Malignant Melanoma: A Meta-Analysis on Monotherapy Vs Combination Therapy. <i>Journal of Cancer</i> , 2022, 13, 3091-3102.	1.2	4
34	Recent Developments Related to the Toxic Side Effects of Immunosuppressive Combination Therapy. <i>Advances in Clinical Medicine</i> , 2022, 12, 7292-7299.	0.0	0
35	Real-world experience with anti-programmed cell death protein 1 immunotherapy in patients with esophageal cancer: A retrospective single-center study. <i>Frontiers in Oncology</i> , 0, 12, .	1.3	1
36	Immune Checkpoint Inhibitor-Induced Myositis/Myocarditis with Myasthenia Gravis-like Misleading Presentation: A Case Series in Intensive Care Unit. <i>Journal of Clinical Medicine</i> , 2022, 11, 5611.	1.0	5
37	Photothermal Nano-Vaccine Promoting Antigen Presentation and Dendritic Cells Infiltration for Enhanced Immunotherapy of Melanoma via Transdermal Microneedles Delivery. <i>Research</i> , 2022, 2022, .	2.8	6
38	RNA modifications: importance in immune cell biology and related diseases. <i>Signal Transduction and Targeted Therapy</i> , 2022, 7, .	7.1	74

#	ARTICLE	IF	CITATIONS
39	Integration of gold nanodendrites and immune checkpoint blockers to achieve highly efficient photothermal immunotherapy for eradicating primary and distant metastatic osteosarcoma. <i>Materials Today Nano</i> , 2022, 20, 100268.	2.3	5
40	Development and characterization of a novel human <sc>CD137</sc> agonistic antibody with anti-tumor activity and a good safety profile in non-human primates. <i>FEBS Open Bio</i> , 2022, 12, 2166-2178.	1.0	3
41	Cancer Immunotherapy <i>Clinical Trials</i> . , 2022, , 1-24.		0
42	Assembly of Biologically Functional Structures by Nucleic Acid Templating: Implementation of a Strategy to Overcome Inhibition by Template Excess. <i>Molecules</i> , 2022, 27, 6831.	1.7	0
43	Arrhythmic events associated with immune checkpoint inhibitors therapy: A real-world study based on the Food and Drug Administration Adverse Event Reporting System database. <i>Cancer Medicine</i> , 2023, 12, 6637-6648.	1.3	4
44	Immune-related adverse events: A bibliometric analysis. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	10
45	Context-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer. <i>Cancer Discovery</i> , 2023, 13, 278-297.	7.7	37
46	Distinct T-cell sub-clusters may serve as biomarkers for immune related adverse events. <i>Cell Reports Medicine</i> , 2023, 4, 100902.	3.3	0
47	Microbiome influencers of checkpoint blockade-associated toxicity. <i>Journal of Experimental Medicine</i> , 2023, 220, .	4.2	13
50	Implication of the Gut Microbiome and Microbial-Derived Metabolites in Immune-Related Adverse Events: Emergence of Novel Biomarkers for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2023, 24, 2769.	1.8	7
51	Boosting Checkpoint Immunotherapy with Biomaterials. <i>ACS Nano</i> , 2023, 17, 3225-3258.	7.3	20
52	Gamma delta T-cell-based immune checkpoint therapy: attractive candidate for antitumor treatment. <i>Molecular Cancer</i> , 2023, 22, .	7.9	22
53	Porphyrin-based metal-organic framework nanocrystals for combination of immune and sonodynamic therapy. <i>Nano Research</i> , 2023, 16, 9633-9641.	5.8	5
54	An unusual case of immune-related gastritis in one patient receiving toripalimab therapy. <i>Immunotherapy</i> , 2023, 15, 335-342.	1.0	1
55	Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. <i>Cancer Immunology, Immunotherapy</i> , 2023, 72, 2217-2231.	2.0	2
56	Dietary fungi in cancer immunotherapy: From the perspective of gut microbiota. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	0
57	Chemotherapy-Sensitized <i>In Situ</i> Vaccination for Malignant Osteosarcoma Enabled by Bioinspired Calcium Phosphonate Nanoagents. <i>ACS Nano</i> , 2023, 17, 6247-6260.	7.3	4
58	Transcatheter arterial chemoembolization plus apatinib with or without camrelizumab for unresectable hepatocellular carcinoma: a multicenter retrospective cohort study. <i>Hepatology International</i> , 2023, 17, 915-926.	1.9	2

#	ARTICLE	IF	CITATIONS
59	Incidence of serious adverse events caused by tyrosine kinase inhibitor treatment following immune checkpoint inhibitor therapy in advanced NSCLC patients with oncogenic driver alterations. <i>Cancer Immunology, Immunotherapy</i> , 0, , .	2.0	1
69	Emerging evidence for adapting radiotherapy to immunotherapy. <i>Nature Reviews Clinical Oncology</i> , 2023, 20, 543-557.	12.5	36
80	Tumor-responsive dynamic nanoassemblies for boosted photoimmunotherapy. <i>Nano Research</i> , 2023, 16, 11125-11138.	5.8	0
82	Bioengineering translational models of lymphoid tissues. , 2023, 1, 731-748.		2
92	Editorial: Manipulation of immune-vascular crosstalk in solid tumors. <i>Frontiers in Immunology</i> , 0, 14, .	2.2	0
107	Mechanisms of immune checkpoint inhibitors: insights into the regulation of circular RNAs involved in cancer hallmarks. <i>Cell Death and Disease</i> , 2024, 15, .	2.7	0